Bevacizumab and anlotinib combination therapy acts via HIF-1α suppression to exert synergistic anti-angiogenic and anti-tumor effects in non-small cell lung cancer

IntroductionTumor angiogenesis is required for the progression of non-small cell lung cancer (NSCLC), and anti-vascular endothelial growth factor (anti-VEGF) antibody bevacizumab and multitarget tyrosine kinase inhibitor anlotinib are anti-cancer treatment options, the combined effect of which in NS...

Descrición completa

Detalles Bibliográficos

Principais autores:	Nafeisha Simayi, Jiaying Li, Junkai Hu, Ning Jia, Rongxue Wan, Jinbiao Xie, Wenhua Huang
Formato:	Artigo
Idioma:	Inglês
Publicado:	Frontiers Media S.A. 2025-09-01
Series:	Frontiers in Immunology
Assuntos:	microfluidic chip non-small cell lung cancer bevacizumab anlotinib angiogenesis epithelial–mesenchymal transition
Acceso en liña:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1613368/full
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!